Market Analysis and Insights: Global Chemotherapy-Induced Nausea and Vomiting Drugs Market
The global Chemotherapy-Induced Nausea and Vomiting Drugs market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Chemotherapy-Induced Nausea and Vomiting Drugs Scope and Market Size
The global Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy-Induced Nausea and Vomiting Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Existing Drugs
Akynzeo (Netupitant-Palonosetron FDC)
Aloxi (Palonosetron)
Emend (Aprepitant)
Kytril Generic (Granisetron)
Zofran Generic (Ondansetron)
Pipeline Drugs
SUSTOL (Granisetron Injection extended release)
Rolapitant

Segment by Application
Serotonin Receptor Antagonists
NK1 Receptor Antagonists

The Chemotherapy-Induced Nausea and Vomiting Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Merck & Co., Inc.
GlaxoSmithKline plc
Tesaro, Inc.
Helsinn Group
F. Hoffmann-La Roche Ltd.
Heron Therapeutics, Inc.
Dr. Reddy's Laboratories Ltd.
Acacia Pharma
Sun Pharmaceutical Industry Ltd.
Otsuka Holdings Co., Ltd.